Product Description
SHR-1906 is being developed by Guangdong Hengrui Pharmaceutical for the treatment of Unspecified Adult Solid Tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04842630?term=SHR-1906&draw=2&rank=2)
Mechanisms of Action: CTGF Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangdong Hengrui Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20230121 |
CTR20230121 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2024-08-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|